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Abstract
Background:  Hypoparathyroidism  is  one  of  the  most  frequent  complications  of  neck  surgery.
The treatment  is  currently  medical;  however  this  involves  several  complications  secondary
to high  doses  of  calcium  and  vitamin  D,  thus  making  parathyroid  allotransplantation  a  good
management  option.
Material  and  methods: Patients  with  hypoparathyroidism  were  selected  in  the  April-December
period of  2011  in  the  general  surgical  clinic.  They  were  between  16  and  65  years,  and  ingested
high doses  of  calcium.  The  donors  were  patients  with  primary  and  secondary  hyperparathy-
roidism, and  the  transplants  were  performed  in  relation  to  blood  group  and  human  leucocyte
antigen.
Results: Five  parathyroid  allografts  were  performed.  All  the  patients  had  iatrogenic
hypoparathyroidism,  all  women  with  a  mean  age  of  49.8  years.  The  graft  was  implanted  under
local anaesthesia  in  the  non-dominant  forearm.  Four  of  the  patients  are  so  far  considered  func-
tional due  to  the  increase  in  paratohormone,  and  demonstrating  its  function  by  scintigraphy
with sestamibi.  One  of  the  patients  showed  no  increase  in  paratohormone  or  imaging  studies
that demonstrate  its  functionality.  After  a  two  year  follow-up  the  graft  remains  functional  but
with oral  calcium  intake  at  a  lower  dose  than  before  transplantation.  None  of  the  patients  had
immunosuppression  side  effects.
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Conclusions:  In  this  study,  allogeneic  unrelated  living  parathyroid  transplant  with  an  immuno-
suppressive  regimen  of  six  months  has  proven  to  be  a  safe  alternative  treatment  to  improve
quality of  life  by  decreasing  the  excessive  calcium  intake  and  improving  physical  activity  with
adequate  graft  survival  at  24  months  follow-up.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Alotrasplante  de  paratiroides:  seguimiento  a  2  an˜os
Resumen
Antecedentes:  El  hipoparatiroidismo  es  una  complicación  frecuente  de  la  cirugía  de  cuello.
Actualmente  el  tratamiento  es  médico,  y  conlleva  complicaciones  secundarias  a  altas  dosis  de
calcio y  vitamina  D,  por  lo  que  el  alotrasplante  es  una  opción  de  manejo.
Material  y  métodos:  Seleccionamos  pacientes  con  hipoparatiroidismo  en  el  periodo  abril-
diciembre  de  2011  de  la  consulta  de  Cirugía  General,  de  entre  16  y  65  an˜os,  que  ingirieran
dosis altas  de  calcio.  Los  donantes  fueron  pacientes  con  hiperparatiroidismo  primario  y  secun-
dario; los  trasplantes  se  realizaron  en  relación  con  grupo  sanguíneo  y  antígeno  leucocitario
humano.
Resultados:  Se  realizaron  5  alotrasplantes  de  paratiroides,  en  pacientes  con  antecedente  de
hipoparatiroidismo  iatrogénico,  mujeres  con  una  edad  promedio  de  49.8  an˜os;  al  tener  el  injerto
bajo anestesia  local  se  implanta  en  el  antebrazo  no  dominante.  De  los  trasplantes  realizados  4  se
consideran  funcionales  por  elevación  de  paratohormona  y  se  ha  demostrado  su  función  mediante
gammagrama  sestamibi.  Una  de  las  pacientes  no  mostró  aumento  de  paratohormona  ni  los  estu-
dios de  imagen  demostraron  la  funcionalidad  del  injerto.  A  2  an˜os  de  seguimiento  se  mantienen
con el  injerto  funcional,  pero  aún  con  ingesta  de  calcio  oral  aunque  a  más  bajas  dosis  que  antes
del trasplante.  Ninguna  de  las  pacientes  tuvo  efectos  secundarios  a  la  inmunosupresión.
Conclusiones:  El  alotrasplante  de  paratiroides  de  vivo  no  relacionado  con  esquema  de  inmuno-
supresión ha  demostrado  ser  un  tratamiento  alternativo  seguro,  para  mejorar  la  calidad  de
vida al  disminuir  la  ingesta  excesiva  de  calcio  y  mejorar  la  actividad  física  de  los  pacientes,  con
sobrevida  del  injerto  a  24  meses  de  seguimiento.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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We  present  the  clinical  results  of  ﬁve  patients  whoBackground
Hypoparathyroidism  is  one  of  the  most  common  compli-
cations  in  neck  surgery  (thyroid  glands,  parathyroid  glands,
etc.);  its  incidence  is  associated  with  the  type  of  disease
or  surgical  technique  used,  as  well  as  with  the  surgeon’s
experience.  It  is  estimated  that  10%  of  the  patients  who
undergo  surgery  due  to  thyroid  carcinoma  will  develop
hypoparathyroidism.1
Nowadays,  the  only  treatment  for  hypoparathyroidism
is  calcium  and  vitamin  D  supplements,  which  for  a  lack
of  negative  feedback  is  frequently  associated  with  over-
doses  or  insufﬁcient  doses,  leading  to  either  hypo-  or
hypercalcaemia  complications.  With  the  purpose  of  avoiding
complications  associated  with  medical  treatment,  several
surgical  techniques  have  been  attempted,  such  as  the  auto-
transplantation  of  fragments  of  parathyroid  tissue.  However,
many  times  it  is  not  possible  to  have  parathyroid  tissue  for
this  procedure.
r
hIn  1971,  Wells  et  al.  performed  a  living-related  donor
llotransplantation,  removing  two  parathyroid  glands  and
mplanting  them  in  his/her  son,  who  had  previously
eceived  a  renal  transplantation.  After  a  30-month  follow-
p,  endocrine  activity  was  found  in  this  implant.2 Since  then,
here  have  been  several  reports  about  parathyroid  allotrans-
lantations  with  diverse  results.3--5 However,  this  procedure
equires  immunosuppression,  which  involves  some  well-
nown  side  effects.
One  of  the  main  issues  related  to  allotransplantations
s  implant  rejection,  and  implant  survival  and  functionality
ill  only  be  possible  when  the  tissue  is  devoid  of  antigenic
ells  that  strongly  express  human  leucocyte  antigen  (HLA)
lass  II.  Parathyroid  cells  weakly  express  HLA  class  I anti-
ens,  which  are  not  responsible  for  the  rejection  reaction,
o  this  type  of  tissue  generates  a  low  incidence  rate  of
ejection.6eceived  parathyroid  allotransplantation  due  to  postsurgical
ypoparathyroidism  after  a  one-year  follow-up.
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aterial and methods
election  of  donors
atients  between  the  age  of  10  and  65  who  had  primary
r  secondary  hyperparathyroidism;  not  related  to  the  recip-
ents.  Serological  testing  for  hepatitis  B  virus,  hepatitis
 virus,  human  immunodeﬁciency  virus,  cytomegalovirus
gG  and  IgM  antibodies,  Epstein--Barr  and  puriﬁed  protein
erivative,  as  well  as  HLA,  blood  group  and  Rh  factor  was
erformed  in  all  potential  donors  to  ﬁnd  the  ideal  recipient
f  the  tissue.  Anyone  who  tested  positive  for  any  study  or
ho  had  a  history  of  neoplasia  was  dismissed  as  a  potential
onor.
All  patients  signed  an  informed  consent  to  accept  the
ransplantation.  This  study  was  approved  by  the  Ethics  Com-
ittee  of  the  Hospital  de  Especialidades  del  Centro  Medico
acional  de  Occidente,  registration  number  R-2012-1301-
4.
onservation  of  tissue
nce  the  donor’s  parathyroid  tissue  was  removed,  it
as  prepared  for  immediate  transplantation  following  the
arathyroidectomy.  The  tissue  was  cut  in  fragments  of
pproximately  2  to  3  mm,  and  one  fragment  was  sent  for
ntraoperative  analysis  to  rule  out  malignancy.  Subsequently,
ach  of  the  fragments  was  placed  inside  a  sterile  storage
ube  with  Celsior® preservation  solution  or  Custodiol® to  be
ransplanted  immediately  after  removal.
election  of  recipients
atients  with  hypoparathyroidism  were  identiﬁed  at  the  gen-
ral  surgery  outpatient  service,  aged  between  16  and  65,
ho  had  secondary  hypoparathyroidism  caused  by  surgi-
al  procedure  (thyroidectomy),  with  laboratory  and  imaging
tudies  (parathyroid  gland  gammagram)  that  proved  they
ad  hypoparathyroidism.  In  addition,  their  calcium  carbon-
te  intake  had  to  be  higher  than  2.5  g/day,  their  calcitriol
ntake  higher  than  1  mcg/day,  and  they  had  to  have  gastric
ntolerance  to  calcium  and/or  vitamin  D.
urgical  technique  for  transplantation
n  incision  of  approximately  3  cm  was  made  in  the  non-
ominant  forearm  under  local  anaesthesia  with  Xylocaine®
%.  The  dissection  reached  the  fascia;  3  to  4  fragments  of
arathyroid  tissue  were  placed  in  groups  of  4,  which  were
arked  with  metallic  staples,  and  then  the  wound  was  tack-
ed.  The  forearm  was  chosen  as  the  implant  site  since  it
s  an  area  with  a  well-developed  vascular  network,  which
ould  provide  a  sufﬁcient  amount  of  oxygen  and  nutrients
o  the  implant  tissue.  It  is  also  an  area  in  which  it  is  easy  to
erform  ultrasonographies  and  control  scintigrams,  as  tissue
dentiﬁcation  is  simple.
8
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mmunosuppression  scheme
n  immunosuppression  scheme  was  used,  which  consisted
f  an  induction  dose  of  methylprednisolone  250  mg.  Then  a
yclosporine  A  scheme  was  used,  calculated  at  5  mg/kg/day
uring  the  ﬁrst  week,  maintaining  serum  levels  between
00  and  250,  and  decreasing  the  dose  to  suspend  it  after
 months;  and  20  mg  of  prednisone  was  used  during  the  ﬁrst
eek,  15  mg  during  the  second  week,  10  mg  during  the  third
eek,  5  mg  during  the  fourth  week  and  a  maintenance  dose
f  2.5  mg  was  used  until  6  months  were  completed.  None  of
he  patients  had  side  effects  from  the  cyclosporine.
onitoring  the  implant’s  functioning
efore  the  transplantation,  calcium  and  serum  parathy-
oid  hormone  (PTH)  samples  were  taken  from  all  the
atients.  PTH  measurement  was  performed  through  chemi-
uminescence,  using  Siemens’  ADVIA  Centaur® XP  equip-
ent.  After  the  transplantation,  samples  were  taken  from
he  implanted  arm  to  check  the  concentrations  of  calcium
nd  PTH  on  post-transplant  months  1,  3,  6,  9,  12  and  24.
he  implant  was  considered  functional  when:  (1)  there
as  an  increase  in  PTH  compared  to  its  pre-surgical  value;
2)  the  implant  was  detected  by  means  of  a gammagram
ith  parathyroid  sestamibi  using  Philips  Precedence;  (3)  the
mplant  and  its  vascularity  was  detected  through  an  ultra-
onography,  and  (4)  the  patient  reduced  his/her  oral  calcium
ntake.  The  implant  was  considered  dysfunctional  when:  (1)
erum  PTH  levels  were  undetectable;  (2)  there  were  clin-
cal  symptoms  such  as  tingling  or  numbness,  and  (3)  there
ere  hypocalcaemia  data  that  forced  an  increase  in  the  oral
alcium  dose.
esults
ive  patients  with  hypoparathyroidism  were  included,  all
emales.  The  aetiology  of  four  patients  was  iatrogenic
ypoparathyroidism  after  thyroid  gland  surgery.  Initially,  one
f  the  patients  had  primary  hyperparathyroidism  and  then
ypoparathyroidism,  in  spite  of  having  received  an  implant
rom  her  own  gland.  The  median  age  of  the  patients  was
9.8  years.  All  the  patients  received  an  implant  from  differ-
nt  donors,  all  of  whom  had  primary  hyperparathyroidism.
hey  were  selected  according  to  their  blood  group  (ABO)
henotype;  two  were  A+,  two  O+  and  one  B+.
The  average  level  of  serum  PTH  prior  transplantation  was
f  2.2  pg/ml  (SD  1.62);  calcium  was  8.14  mg/dl  (SD  0.44),
hosphorus  was  5.08  mg/dl  (SD  0.44)  and  urine  calcium  was
46.60  mg/dl  (SD  85.27).
During  the  follow-up,  the  numbers  for  serum  PTH  did  not
ncrease  signiﬁcantly  during  the  ﬁrst  trimester;  the  median
as  of  2.82  pg/ml  (SD  1.45).  However,  at  the  third-trimester
ollow-up  there  was  a  signiﬁcant  increment  with  a  median  of
.65  pg/ml  (SD  1.58).  At  the  24-month  follow-up,  the  num-
ers  were  still  on  the  rise,  with  a  median  of  19.07  pg/ml  (SD
.46).Mean  presurgical  levels  of  serum  calcium  were  of
.14  mg/dl  (SD  0.44).  Its  increment  was  more  prominent  dur-
ng  the  third  trimester,  with  a  mean  of  9.26  mg/dl  (SD  0.41).
t  the  2-year  follow-up,  the  amount  of  calcium  was  stable,
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Figure  1  Enlarged  parathyroid  gland  gammagram  in  forearm Figure  2  Forearm  ultrasonography  after  24  months,  where
the implant  can  be  seen  (arrow).
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o24 months  after  transplantation,  showing  the  implant  detecting
sestamibi.
with  a  mean  of  8.51  mg/dl  (SD  0.1);  although  there  was  no
signiﬁcant  increase  in  calcium,  it  should  be  pointed  out  that
at  the  2-year  follow-up  the  patients’  intake  of  calcium  car-
bonate  was  lower  and  they  had  almost  the  same  levels  of
serum  calcium  as  prior  to  transplantation.
Throughout  the  follow-up  period,  phosphorus  levels  were
high  and  although  during  the  ﬁrst  month,  when  num-
bers  were  within  a  normal-high  range,  with  a  mean  of
4.6  mg/dl  (SD  0.66),  at  the  12-month  follow-up  the  mean
was  5.2  mg/dl  (SD  0.54),  and  at  the  last  24-month  follow-up
the  levels  of  phosphorus  were  controlled,  with  a  mean  of
5.6  mg/dl  (SD  0.77).
Presurgical  urine  calcium  values  were  of  146.60  mg/dl  (SD
85.27),  and  after  24  months,  the  mean  was  134.54  mg/dl  (SD
18.24).
After  24  months,  the  sestamibi  gammagram  and  the
Doppler  ultrasound  reported  that  the  radiopharmaceutical
detected  an  implant  with  blood  ﬂow  in  four  patients.  In  one
of  the  patients  the  implant  was  not  detected  or  identiﬁed
in  the  ultrasound  (Figs.  1--3).
All  the  patients  received  an  intake  of  calcium  carbon-
ate  of  8.4  g/day.  At  present,  their  mean  intake  is  6  g/day
and  the  implant  is  functional  after  a  two-year  follow-up.
Another  beneﬁt  is  that  they  can  carry  out  their  basic  daily
activities  without  having  signs  of  hypocalcaemia,  which  was
not  possible  before  transplantation  (Table  1).
Table  1  Calcium  intake  before  and  after  transplantation.
Patient  Presurgical  oral
calcium  (g)
Postsurgical
oral  calcium  (g)
1  9  4
2 12  8
3 6  4
4 14  9
5 8  5
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pigure  3  Thyroid  ultrasonography  after  24  months,  where  the
mplant  can  be  seen  (arrow).
iscussion
cute  hypocalcaemia  following  a  parathyroidectomy  due
o  hyperparathyroidism  is  rare  and  has  an  incidence
f  1  to  2%.  Patients  with  higher  risk  are  the  ones
ho  undergo  total  or  near-total  thyroidectomies  of  their
arathyroid  glands,  whether  because  they  have  primary
yperparathyroidism  or  because  they  suffer  from  parathy-
oid  gland  disease  associated  with  kidney  disease  (secondary
r  tertiary  hyperparathyroidism).  After  parathyroid  auto-
ransplantation  was  recognised  as  a  means  of  preventing
ermanent  hypoparathyroidism  in  1976,  allotransplantation
as  attempted  in  patients  for  whom  this  was  the  only
reatment  option,  to  avoid  the  intake  of  high  doses  of  vita-
in  D  and  calcium,  which  increase  the  risk  of  long-term
omplications,  such  as  paraesthesia,  multiorgan  calcinosis
nd  renal  failure.6,7
Parathyroid  allotransplantation  is  a  potential  therapy  for
ermanent  hypoparathyroidism7 with  variable  and  limited
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192  
esults,  despite  having  been  experimentally  recreated  in
nimals  and  humans.7--9
There  are  several  ways  to  perform  parathyroid  allotrans-
lantations,  among  which  is  the  parathyroid-cell  culture,
f  which  it  has  been  reported  the  results  are  not  long-
asting,  with  subsequent  implant  rejection  through  immune
echanisms.10--12 Alginates  were  used  to  protect  the
mplant,  and  before  transplantation  they  were  treated  with
 5%  CO2 atmosphere;  through  this  treatment,  cells  are  pro-
ected  from  an  immune  response  and  results  are  functionally
ore  long-lasting.
In  our  study,  we  decided  to  use  a  living  unrelated  donor;
e  looked  for  compatibility  by  means  of  blood  group  and
LA,  as  well  as  by  an  immunosuppression  scheme  at  low
oses  to  be  able  to  protect  the  implant  from  acute  rejec-
ion,  since  currently  this  has  been  shown  to  have  more
ong-lasting  results,  such  as  the  ones  reported  by  Belda
onzález  et  al.13 We  decided  to  use  a  scheme  similar  to
he  one  for  renal  transplantation,  since  it  allows  recov-
ry  of  the  implant’s  PTH  secretion,  based  on  a  report  by
lechner  et  al.14 who  used  the  same  immunosuppression
cheme  for  renal  transplantation  in  their  study.  It  is  well
nown  that  the  use  of  these  drugs  is  associated  with  high
orbidity  and  toxicity  rates,  so  we  carried  out  a  strict  con-
rol  of  serum  levels  without  seeing  any  complications  during
he  follow-up  period;  therefore,  in  patients  with  permanent
ypoparathyroidism  for  whom  the  only  treatment  option  is
llotransplantation,  the  use  of  these  drugs  can  be  justiﬁed.
Based  on  our  results,  there  was  a  signiﬁcant  increase
n  serum  PTH  in  four  patients  after  a  24-month  follow-up,
nd  the  results  were  similar  to  the  ones  reported  by  Belda
t  al.,13 where  after  a  two-year  follow-up  the  implant  was
till  functional  and  serum  PTH  levels  had  increased;  this
s  why  we  can  state  that  parathyroid  allotransplantation
s  a  good  treatment  option  for  patients  with  hypoparathy-
oidism.
onclusions
n  our  study,  it  was  demonstrated  that  parathyroid  allo-
ransplantation  from  a  living  unrelated  donor  with  an
mmunosuppression  scheme  is  a  safe  alternative  treatment
o  improve  the  patients’  quality  of  life,  with  which  the
xcessive  intake  of  calcium  can  be  reduced,  as  well  as  the
omplications  involved  in  consuming  high  doses  of  calcium.
n  addition,  it  improves  their  quality  of  life  by  allowing
hem  to  do  their  basic  daily  activities  without  signs  of
ypocalcaemia.  At  present,  we  keep  performing  parathy-
oid  transplantations  with  promising  results  at  our  centre,
lthough  treatment  with  calcium  cannot  be  completely  sus-
ended;  clinically,  there  is  evidence  of  an  improvement  in
1J.M.  Hermosillo-Sandoval  et  al.
aily  life  activities  and  a  reduction  of  the  side  effects  asso-
iated  with  the  consumption  of  high  levels  of  calcium.
onﬂict of interest
he  authors  declare  that  there  are  no  conﬂicts  of  interest.
eferences
1. Pattou F, Combemale F, Fabre S, Carnaille B, Decoulx
M, Wemeau J, et al. Hypocalcemia following thyroid
surgery: incidence and prediction of outcome. World J Surg.
1998;22:718--24.
2. Wells SA Jr, Burdick JF, Hattler BG, Christiansen C, Pettigrew
HM, Abe M, et al. The allografted parathyroid gland: eval-
uation of function in the immunosuppressed host. Ann Surg.
1974;180:805--13.
3. Saxe A. Parathyroid transplantation: a review. Surgery.
1984;95:507--26.
4. Alfrey EJ, Perloff LJ, Asplund MW, Dafoe DC, Grossman RA,
Bromberg JS, et al. Normocalcemia thirteen years after success-
ful parathyroid allografting in a recipient of a renal transplant.
Surgery. 1992;111:234--6.
5. Hasse C, Klöck G, Schlosser A, Zimmermann U, Rothmund
M. Parathyroid allotransplantation without immunosuppression.
Lancet. 1997;350:1296--7.
6. Tsuji K, Fuchinoue S, Kai K, Kawase T, Kitajima K, Sawada T,
et al. Culture of human parathyroid cells for transplantation.
Transplant Proc. 1999;31:2697.
7. Feind CR, Weber CJ, Derenoncourt F, Williams GA, Hardy
MA, Reemtsma K. Survival and allotransplantation of cultured
human parathyroids. Transplant Proc. 1979;11:1011--6.
8. Tibell A, Rafael E, Wennberg L, Nordenström J, Bergström
M, Geller RL, et al. Survival of macroencapsulated allogeneic
parathyroid tissue one year after transplantation in nonimmuno-
suppressed humans. Cell Transplant. 2001;10:591--9.
9. Sollinger HW, Mack E, Cook K, Belzer FO. Allotransplantation of
human parathyroid tissue without immunosuppression. Trans-
plantation. 1983;36:599--602.
0. Lee MK, Bae YH. Cell transplantation for endocrine disorders.
Adv Drug Deliv Rev. 2000;42:103--20.
1. Yao CZ, Ishizuka J, Townsend CM Jr, Thompson JC. Success-
ful intracerebroventricular allotransplantation of parathyroid
tissue in rats without immunosuppression. Transplantation.
1993;55:251--3.
2. Tołłoczko T, Woiniewicz B, Sawicki A, Gorski A. Allotransplan-
tation of cultured human parathyroid cells: present status and
perspectives. Transplant Proc. 1997;29:998--1000.
3. Belda González I, del Moral JM, Pérez NM, Soto JB, Orihuela
JA. Parathyroid allotransplantation as permanent treatment in
a renal transplant patient. Spanish. Cir Esp. 2012;90:202--3.4. Flechner SM, Berber E, Askar M, Stephany B, Agarwal A, Milas
M. Allotransplantation of cryopreserved parathyroid tissue for
severe hypocalcemia in a renal transplant recipient. Am J Trans-
plant. 2010;10:2061--5.
